20/04/2020 15:08Updated: 04/20/2020 15:15

The World Health Organization (WHO) has published a study in which, after reviewing the current evidence, concludes that anti-inflammatory drugs non-steroidal, which includes ibuprofen, do not provide benefits or risks to patients infected by the new coronavirus.

“Nowadays no evidence that the use of NSAIDs causes serious adverse events, acute use of medical care, long-term survival or quality of life in patients with Covid-19, “says the United Nations body in the document.

He has reached this conclusion after analyze 73 studies (28 performed in adults, 46 in children, and one in both groups) in which acute viral respiratory infections or common conditions were studied caused by respiratory virusesBut none specifically addressed the novel coronavirus or SARS or MERS.

The review revealed that there is a “very low” certainty on mortality among adults and children, and that they are not “very clear” the effects that these drugs can raise the risk of ischemic and hemorrhagic stroke and myocardial infarction in adults with acute respiratory infections.

There is “little or no difference” between ibuprofen and acetaminophen among children with fever regarding the effects on death.

Similarly, as reported by the WHO, there is “little or no difference” between ibuprofen and paracetamol among children with fever relative to effects on death for all causes, hospitalization for any cause, acute renal failure and acute gastrointestinal bleeding.

Additionally, most studies report that no serious adverse events occurred, or that only mild or moderate adverse events were observed, and no detected scientific evidence Regarding the effects of NSAID use in acute medical care utilization, explicit measures of quality of life or survival long-term.

No evidence found direct from patients with Covid-19, SARS or MERS. Therefore, all included evidence should be considered indirect evidence regarding the use of NSAIDs before or during the management of the new coronavirus“, has settled the WHO in the report.


Leave a comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.